CHEST Physician
-
Top reads from the CHEST journal portfolio – June 2025
Editorial Board members share their insights on journal articles about observation vs surgery in pulmonary subsolid nodules, initial opioid exposure in the ICU, and clinical outcomes of cardiac arrythmias in PAH.
-
Brensocatib awaits FDA approval for bronchiectasis following ASPEN results
Experts Mark Metersky, MD, FCCP; Pamela J. McShane, MD; and Charles L. Daley, MD, FCCP, discuss the potential clinical implications of addressing inflammation in bronchiectasis—from reduced exacerbations and slowed decline in FEV to improved quality of life.
-
MATINEE shows positive results for mepolizumab in COPD
Experts Frank Sciurba, MD, FCCP, and Gerard J. Criner, MD, FCCP, said clinicians have a second option for treating patients with high type 2 inflammation now that the FDA has approved the drug for those with an eosinophilic phenotype.
-
Study to test efficacy of tezepelumab for treating asthma exacerbations in the emergency department
Diego J. Maselli, MD, FCCP, said the TERAA trial will provide needed evidence on the use of biologics in the acute care setting.
-
Platelet and fresh frozen plasma transfusion guidelines in critical care
New guidelines from CHEST promote a more restrictive approach to platelet and fresh frozen plasma use in the ICU in order to enhance patient safety and conserve resources.
-
CHEST 2025: An early look at the headlining topics
Get a sneak peek at the session topics each chest medicine niche will be covering at CHEST 2025 in Chicago.
-
Pride Month: Honoring identity and celebrating diversity
This Pride Month, let us lead with kindness and celebrate the vibrant spectrum of human identity that enriches our work as clinicians.
-
Shared decision-making in PAH
Shared decision-making is a collaborative process where clinicians and patients make informed health care decisions together, balancing medical evidence with patient values, which is especially important in complex conditions like PAH.
-
Opening the flood gates: Pleural complications of immune checkpoint inhibitors
The pulmonary and medical oncology community must start to consider pleural complications as a potential risk of immune checkpoint inhibitor therapy.
-
Pooled data suggest sotatercept as novel disease-modifying therapy for PAH
Aaron B. Waxman, MD, PhD, FCCP, said he believes the drug will become a first-line therapy option, but questions remain regarding when to initiate treatment.
